Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 7/20 | 0.62 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.62 |
| ▸ | ANPEP | P15144 | 1/20 | 0.50 |
| ▸ | LAP3 | P28838 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9696199 | 0.90 | FOLH1 (0.65) | FOLH1GRM3NAALAD2ANPEPLAP3 | |
| SCHEMBL7652096 | 0.84 | FOLH1 (0.65) | FOLH1GRM3NAALAD2 | |
| SCHEMBL9715079 | 0.84 | CHRM1 (0.52) | FOLH1GRM3NAALAD2ANPEPLAP3 | |
| SCHEMBL13472032 | 0.84 | FOLH1 (0.65) | FOLH1GRM3NAALAD2 | |
| SCHEMBL12118136 | 0.84 | FOLH1 (0.65) | FOLH1GRM3NAALAD2 | |
| SCHEMBL7605870 | 0.83 | FOLH1 (0.59) | FOLH1GRM3NAALAD2ANPEPLAP3 | |
| SCHEMBL9696208 | 0.82 | FOLH1 (0.60) | FOLH1GRM3ANPEPLAP3 | |
| SCHEMBL9697359 | 0.82 | ANPEP (0.56) | ANPEPLAP3 | |
| SCHEMBL9697381 | 0.81 | SLC1A2 (0.53) | FOLH1ANPEPLAP3 | |
| SCHEMBL14116536 | 0.81 | FOLH1 (0.61) | FOLH1GRM3NAALAD2ANPEPLAP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6413948-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | GUILFORD PHARMACEUTICALS INC. | 2002-07-02 | — | — | US | claimed |
| JP-2002514185-A | — | — | 2002-05-14 | — | — | JP | claimed |
| US-6384022-B1 | ENZYME INHIBITORS | GUILFORD PHARMACEUTICALS INC. | 2002-05-07 | — | — | US | claimed |
| JP-2001527084-A | — | — | 2001-12-25 | — | — | JP | claimed |
| EP-1044206-A1 | PRODRUGS OF NAALADASE INHIBITORS | Guildford Pharmaceuticals Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| US-5977090-A | Pharmaceutical compositions and methods of treating compulsive disorders using NAALADase inhibitors | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-02 | — | — | US | claimed |
| EP-0949922-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-10-20 | — | — | EP | claimed |
| WO-1999033848-B1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARM INC (US) | 1999-08-12 | — | — | WO | claimed |
| WO-1999033849-A1 | PRODRUGS OF NAALADASE INHIBITORS | GUILDFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | claimed |
| WO-1998013044-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING COMPULSIVE DISORDERS USING NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| US-6028216-A | Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999033848-A1 | PROCESS FOR PREPARING ENANTIOMER-ENRICHED HYDROXYPHOSPHINYL DERIVATIVES | GUILFORD PHARMACEUTICALS INC. (US) | 1999-07-08 | — | — | WO | disclosed |